ADC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Luzzatto, C
Right arrow Articles by Guglielmi, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luzzatto, C
Right arrow Articles by Guglielmi, M
Arch Dis Child 2000;82:316-318 ( April )

Article

Sclerosing treatment of lymphangiomas with OK-432 C Luzzatto, P Midrio, Z Tchaprassian, M Guglielmi

Divisione di Chirurgia Pediatrica, Via Giustiniani 3, 35128 Padova, Italy

Correspondence to: Dr Luzzatto

Accepted 16 November 1999

Over a period of seven years, 15 patients (aged from birth to 15 years; median 22 months) with lymphangioma were treated with OK-432; they received a mean of three injections each. Ten received OK-432 as first line treatment; five were treated after surgery (three had a residual lymphangioma after incomplete removal and two had a late recurrence). OK-432 proved to be effective for primitive as well as for residual and recurrent lymphangioma. Seven cases were macrocystic; complete regression was obtained in all. Five cases were microcystic: two had more than 50% regression, and three less than 50%. Three cases were mixed, with both large and microscopic cysts: one had more than 50% regression, and two less than 50%. These last two cases underwent surgery after the sclerosing treatment. The results obtained were excellent in 100% of macrocystic cases; a shrinkage in size was obtained in all microcystic cases. OK-432 is therefore proposed as a first line option for treatment of lymphangiomas.


Keywords: OK-432; lymphangioma

© 2000 by Archives of Disease in Childhood


This article has been cited by other articles:


Home page
 Am. J. Neuroradiol.Home page
M.H. Rho, D.W. Kim, J.S. Kwon, S.W. Lee, Y.S. Sung, Y.K. Song, M.G. Kim, and S.G. Kim
OK-432 Sclerotherapy of Plunging Ranula in 21 Patients: It Can Be a Substitute for Surgery.
AJNR Am. J. Neuroradiol., May 1, 2006; 27(5): 1090 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
C. M. Giguere, N. M. Bauman, Y. Sato, D. K. Burke, J. H. Greinwald, S. Pransky, P. Kelley, K. Georgeson, and R. J. H. Smith
Treatment of Lymphangiomas With OK-432 (Picibanil) Sclerotherapy: A Prospective Multi-institutional Trial
Arch Otolaryngol Head Neck Surg, October 1, 2002; 128(10): 1137 - 1144.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
H. Rowley, A. R. Perez-Atayde, P. E. Burrows, and R. Rahbar
Management of a Giant Lymphatic Malformation of the Tongue
Arch Otolaryngol Head Neck Surg, February 1, 2002; 128(2): 190 - 194.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2000 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health